This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

• Datamonitor Healthcare estimates that in 2016, there were approximately 88.5 million prevalent cases of celiac disease worldwide, and forecasts that number to increase to 97.4 million prevalent cases by 2025.
• Prevalence proportions of celiac disease are highest in Europe and Northern America, and lowest in Africa and Oceania.
• All industry-sponsored drugs in active clinical development for celiac disease are in Phase I or Phase II. Therapies in development for celiac disease focus on targets such as gluten, interleukin 15 receptor, zonulin and zonulin receptor, OX40/CD134 and OX40L, and T-cell receptor. Pipeline drugs for celiac disease are administered orally, as well as via intravenous and intradermal formulations.
• High impact upcoming events for drugs in the celiac disease space comprise topline Phase III trial results for INN-202. There have been six licensing and asset acquisition deals involving celiac disease drugs during 2013–18. The $0.1m agreement between Intrexon and two startups, Genten Therapeutics and CRS Bio, to develop disease-modifying therapies through Intrexon’s proprietary ActoBiotics Lactococcus lactis platform was the only deal with a disclosed value.
• The distribution of clinical trials across Phase I–III indicates that the majority of trials for celiac disease have been in the midphase of development, with 90% of trials in Phase II, and only 10% in Phase I.
• The US has a substantial lead in the number of celiac disease clinical trials globally.
• Innovate Biopharmaceuticals has the highest number of completed trials for celiac disease, with six trials.
• Innovate Biopharmaceuticals leads industry sponsors with the highest number of clinical trials for celiac disease